¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"phase III clinical trial"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • clinical diagnosis
    ÀÓ»óÁø´Ü
  • clinical efficacy
    ÀÓ»óÈ¿´É
  • clinical epidemiologist
    ÀÓ»ó¿ªÇÐÀÚ
  • clinical epidemiology
    ÀÓ»ó¿ªÇÐ
  • clinical finding
    ÀÓ»ó¼Ò°ß
  • clinical laboratory
    ÀÓ»ó°Ë»ç½Ç
  • clinical manifestation
    ÀÓ»óÁõ»ó, ÀÓ»ó¼Ò°ß
  • clinical material
    Àӻ󰡰˹°, ÀÓ»ó°Ëü
  • clinical medicine
    ÀÓ»óÀÇÇÐ
  • clinical otosclerosis
    ¹ßÇö±Í°æÈ­Áõ
  • clinical pathology
    ÀÓ»óº´¸®ÇÐ
  • clinical record
    ÀÓ»ó±â·Ï
  • clinical root
    ÀÓ»óÄ¡¾Æ»Ñ¸®, ÀÓ»óÄ¡±Ù
  • clinical sign
    ÀÓ»ó¡ÈÄ
  • clinical significance
    ÀÓ»óÀûÁ߿伺
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • latent phase
    ÀáÀç±â , Àẹ±â
  • plateau phase
    ÆíÆò±â, °íÁ¶±â
  • relaxation phase
    À̿ϱâ, À̿ϻó
  • resolution phase
    ÇØ¼Ò±â
  • resting phase
    È޽ıâ
  • solid phase
    °íü»ó
  • stance phase
    µðµõ±â, ÀÔ°¢±â
  • swing phase
    Èçµê±â, À¯°¢±â
  • synaptic phase
    ¿¬Á¢±â
  • expiratory phase time
    ³¯¼û½Ã°£, È£±â½Ã°£
  • inspiratory phase time
    µé¼û½Ã°£, Èí±â½Ã°£
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • clinical crown
    ÀÓ»óÄ¡¾Æ¸Ó¸®, ÀÓ»óÄ¡¾Æ°ü
  • clinical data
    ÀÓ»óÀÚ·á
  • clinical diagnosis
    ÀÓ»óÁø´Ü
  • clinical efficacy
    ÀÓ»óÈ¿´É
  • clinical epidemiologist
    ÀÓ»ó¿ªÇÐÀÚ
  • clinical epidemiology
    ÀÓ»ó¿ªÇÐ
  • clinical finding
    ÀÓ»ó¼Ò°ß
  • clinical laboratory
    ÀÓ»ó°Ë»ç½Ç
  • clinical manifestation
    ÀÓ»óÁõ»ó, ÀÓ»ó¼Ò°ß
  • clinical material
    Àӻ󰡰˹°, ÀÓ»ó°Ëü
  • clinical medicine
    ÀÓ»óÀÇÇÐ
  • clinical mycology
    ÀÓ»óÁø±ÕÇÐ
  • clinical otosclerosis
    ¹ßÇö±Í°æÈ­Áõ
  • clinical record
    ÀÓ»ó±â·Ï
  • clinical root
    ÀÓ»óÄ¡¾Æ»Ñ¸®
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • hyperlipoproteinemia type III
    °íÁö´Ü¹éÇ÷Áõ III
  • hyperproteinemia type III
    ´Ü¹é°úÀ×Ç÷(Áõ) III Çü
  • hypersensitivity reactions,type iii(imune complex-mediated)
    IIIÇü
  • platelet factor III
    Ç÷¼ÒÆÇÁ¦»ïÀÎÀÚ.
  • procollagen III peptide
    ÇÁ·ÎÄݶó°Õ III ÆéƼµå
  • pseudounipolar(bipolar III) disorder
    °¡¼º ´Ü±Ø¼º(¾ç±Ø¼º III)Àå¾Ö(º´).
  • 3D phase contrast angiography
    3Â÷¿ø À§»ó ´ëÁ¶ Ç÷°üÁ¶¿µ¼ú
  • DNA synthetic phase
    DNA ÇÕ¼º±â
  • Go phase
    Go±â
  • accelerated death phase
    °¡¼Ó»ç¸ê±â(˧ËÛË×ËÎË»).
  • acceleration phase
    ÃËÁø±â, °¡¼Ó±â(Ê¥áÜÑ¢).
  • acute phase protein
    ±Þ¼ºº´±â´Ü¹éÁú
  • acute phase reactant
    ±Þ¼º±â ÀÛ¿ë¹°Áú
  • acute phase reaction
    ±Þ¼º±â¹ÝÀÀ(¡­Ñ¢Úãëë)
  • acute phase reactive protein
    ±Þ¼º±â ¹ÝÀÀ¼º ´Ü¹é.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • group III fiber
    Á¦¥²¤Çí·A.
  • hyperlipoproteinemia type III
    °íÁö´Ü¹éÇ÷Áõ III
  • hyperproteinemia type III
    ´Ü¹é°úÀ×Ç÷(Áõ) III Çü
  • hypersensitivity reactions,type iii(imune complex-mediated)
    IIIÇü
  • oculomotor nerve (iii)
    ´«µ¹¸²½Å°æ
  • os metacarpale III ³ª
    ¼Â°¼Õ¹Ù´Ú<Áß¼ö>»À, Á¦»ïÁß¼ö°ñ(ð¯ß²ñéâ¢Íé).
  • platelet factor III
    Ç÷¼ÒÆÇÁ¦»ïÀÎÀÚ.
  • procollagen III peptide
    ÇÁ·ÎÄݶó°Õ III ÆéƼµå
  • pseudounipolar(bipolar III) disorder
    °¡¼º ´Ü±Ø¼º(¾ç±Ø¼º III)Àå¾Ö(º´).
  • third arch (iii)
    ¼Â°±ÁÀÌ
  • type III human T lymphotropic virus
    IIIÇü ÀÎ t¸²ÇÁ¿µ¾ç¼º ¹ÙÀÌ·¯½º
  • luteal phase progestational phase
    Ȳ(»ö)ü±â
  • bacteriology, clinical
    ÀÓ»ó¼¼±ÕÇÐ
  • clinical application
    ÀÓ»óÀûÀÀ¿ë<--Àû¿ë>
  • clinical bacteriology
    ÀÓ»ó¼¼±ÕÇÐ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Inactive phase
    ºñȰµ¿±â
    [¿¾ ¿ë¾î] ÈÞÁö±â
  • Lactiferous phase
    ¼öÀ¯±â
    [¿¾ ¿ë¾î] ¼öÀ¯±â
  • Synaptic phase
    ¿¬Á¢±â
    [¿¾ ¿ë¾î] ¿¬Á¢±â
  • Menstrual phase
    ¿ù°æ±â
    [¿¾ ¿ë¾î] ¿ù°æ±â
  • Postmenstrual phase
    ¿ù°æÈıâ
    [¿¾ ¿ë¾î] ¿ù°æÈıâ
  • Zygotene phase
    Á¢ÇÕ±â
    [¿¾ ¿ë¾î] Á¢ÇÕ±â
  • Go phase
    Á¤Áö±â [Go±â]
    [¿¾ ¿ë¾î] Á¤Áö±â
  • Proliferative phase
    Áõ½Ä±â
    [¿¾ ¿ë¾î] Áõ½Ä±â
  • Implantational phase
    Âø»ó±â
    [¿¾ ¿ë¾î] Âø»ó±â
  • Preimplantational phase
    Âø»óÀü±â
    [¿¾ ¿ë¾î] Âø»óÀü±â
  • Colostral phase
    ÃÊÀ¯±â
    [¿¾ ¿ë¾î] ÃÊÀ¯±â
  • Placental phase
    Źݱâ
    [¿¾ ¿ë¾î] Źݱâ
  • Involutional phase
    ÅðÈ­±â
    [¿¾ ¿ë¾î] ÅðÈ­±â
  • Proleptotene phase
    Dz¼¶À¯±â
    [¿¾ ¿ë¾î] Àü¼¼»ç±â
  • S phase
    ÇÕ¼º±â [S±â]
    [¿¾ ¿ë¾î] ÇÕ¼º±â
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • lateral phase separation
    Ãø¸é»óºÐ¸®(ö°ØüßÀÝÂ×î)
  • log phase
    log ±â(Ñ¢)
  • maximum stationary phase
    ÃÖ´ëÁ¤Áö±â(õÌÓÞïÎò­Ñ¢)
  • mobile phase
    À̵¿»ó(ì¹ÔÑßÈ)
  • negative phase
    °¨¼Ò±â(Êõá´Ñ¢)
  • normal-phase chromatgoraphy
    Á¤»ó»ó(ïáßÈßÓ) Å©·Î¸¶Åä±×·¡ÇÇ
  • one-phase chromatography
    ÀÏ»ó(ìéßÓ) Å©·Î¸¶Åä±×·¡ÇÇ
  • partition phase
    ºÐ¹è»ó(ÝÂÛÕßÓ)
  • phase
    »ó(ßÓ)
  • phase contrast microscope
    À§»óÂ÷(êÈßÓó¬) Çö¹Ì°æ(ßÓÓßðÎúéÚ°Ìð)
  • phase partition
    »óºÐ¹è(ßÓÝÂÛÕ)
  • phase plate
    »óÆÇ(ßÓ÷ù)
  • phase rule
    »óÀ²(ßÓëÏ)
  • phase shift mutation
    »óÀ̵¿ º¯ÀÌ(ßÓì¹ÔÑܨì¶)
  • phase test
    »ó½ÃÇè(ßÓãËúÐ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • phase axis
    ˤȗ̈
  • phase cancellation artifact
    À§»ó¸»¼Ò(»ó¼â)Àΰø¹°
  • phase coherence
    À§»ó°áÁý
  • phase conjugate symmetry
    À§»óȸº¹´ëĪ, À§»ó°ø¾×´ëĪ
  • phase contrast
    À§»ó´ëÁ¶
  • phase contrast MR angiography
    À§»ó´ëÁ¶ÀÚ±â°ø¸íÇ÷°üÁ¶¿µ¼ú
  • phase curve
    À§»ó°î¼±
  • phase display
    À§»óÇ¥½Ã
  • phase encode direction
    À§»óºÎȣȭ¹æÇâ
  • phase encoding
    À§»óºÎȣȭ
  • phase encoding gradient
    À§»óºÎȣȭ°æ»çµµ(Àå)
  • phase encoding step
    À§»óºÎÈ£´Ü°è
  • phase evolution of fat suppression
    À§»ó¼±È¸ Áö¹æ¾ïÁ¦
  • phase frequency swap
    À§»óÁ֯ļö±³È¯
  • phase image
    À§»ó¿µ»ó
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
RCT radiotherapy and chemotherapy; randomized clinical trial; randomized controlled trial; registered ca...
CR calculation rate; calculus removed; calorie-restricted; cardiac rehabilitation; cardiac resuscitatio...
CS calf serum; campomelic syndrome; carcinoid syndrome; cardiogenic shock; caries-susceptible; carotid ...
ILP inadequate luteal phase; insufficiency of luteal phase; interstitial laser photocoagulation; interst...
SPIA solid-phase immunoabsorption; solid-phase immunoassay
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
apoLp-III Apolipophorin III
APO C-III Apolipoprotein C-III
AP III Atriopeptin III
CA III Carbonic anhydrase III
CIN III Cervical intraepithelial neoplasia grade III
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • clinical chart
    º´»ó ÀÏÁö
  • clinical cytogenetics
    ¼¼Æ÷ À¯ÀüÇÐ
    À¯Àü, Áï ¿°»öü¿Í °ü°èµÈ ¼¼Æ÷ ¿ä¼Ò¸¦ ¿¬±¸ÇÏ´Â À¯ÀüÇÐÀÇ ºÐ¾ß.
  • clinical diagnosis
    ÀÓ»ó Áø´Ü, ÀÓ»óÀû Áø´Ü
    Áø´ÜÀº º¸Åë º´·ÂÀ» ûÃëÇÏ°í ½ÅüÀû ¼Ò°ßÀ» ÃëÇϸç Çʿ信 µû¶ó¼­ °Ë»çÇÏ°í ¾òÀº Á¤º¸¸¦ Á¾ÇÕÇØ¼­ ³»·ÁÁö´Â °ÍÀ¸·Î ÀÌ¿Í °°Àº Áø´ÜÀ» ¼ö¼ú ½Ã¿¡ È®ÀÎÇÑ ¼ö¼ú½Ã Áø´Ü, ¶Ç´Â »çÈÄ ºÎ°Ë¿¡ ÀÇÇØ¼­ È®ÀÎµÈ º´¸® Áø´ÜÀ» ´ëºñ½ÃÄѼ­ ÀÓ»ó Áø´ÜÀ̶ó°í ÇÑ´Ù.
  • clinical examination
    ÀÓ»ó °Ë»ç, ÀÓ»ó ÁøÂû, ÀÓ»óÀû °üÂû
  • clinical hematology
    ÀÓ»ó Ç÷¾×ÇÐ
  • clinical interview
    ÀÓ»ó ¸é´ã
  • clinical locking
    ÀÓ»óÀû °úµÎ °É¸²
  • clinical material
    ÀÓ»ó °¡°Ë¹°, ÀÓ»ó °Ëü
  • clinical modification code
    ÀÓ»ó ¼öÁ¤ ºÎÈ£
  • clinical pharmacology
    ÀÓ»ó ¾à¸®ÇÐ
  • clinical research
    ÀÓ»ó ¿¬±¸
  • clinical resting position
    ÀÓ»óÀû ¾ÈÁ¤À§
  • clinical sign
    ÀÓ»ó ¡ÈÄ
  • clinical skill
    ÀÓ»ó ±â¼ú
  • clinical syndrome
    ÀÓ»ó ÁõÈıº, ÀÓ»óÀû ÁõÈıº
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
randomised controlled trial A clinical trial that involves at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table. Treatment allocations using coin flips, odd-even numbers, patient social security numbers, days of the week, medical record numbers, or other such pseudo- or quasi-random processes, are not truly randomised and a trial employing any of these techniques for patient assignment is designated simply a controlled clinical trial.
(12 Dec 1998)
randomised trial <statistics> A clinical trial in which patients have been randomly assigned to receive either the study drug or alternative treatment, in which neither the patient nor the physician conducting the study know which treatment is being given the patient, and in which the alternative to the study drug is a placebo, the study is conducted at several centres.
(09 Oct 1997)
controlled trial A clinical study in which one group of participants receives an experimental drug while another group receives either a placebo or an approved standard therapy. When participants do not know which group they are in, the trial is blinded.
See: Double-Blind.
(09 Oct 1997)
open-label trial A study in which both researchers and participants know what drug a person is taking and at what dose.
(09 Oct 1997)
trial 1. The act of trying or testing in any manner. Specifically:
Any effort or exertion of strength for the purpose of ascertaining what can be done or effected. "[I] defy thee to the trial of mortal fight." (Milton)
The act of testing by experience; proof; test. "Repeated trials of the issues and events of actions." (Bp. Wilkins)
Examination by a test; experiment, as in chemistry, metallurgy, etc.
2. The state of being tried or tempted; exposure to suffering that tests strength, patience, faith, or the like; affliction or temptation that exercises and proves the graces or virtues of men. "Others had trial of cruel mockings and scourgings." (Heb. Xi. 36)
3. That which tries or afflicts; that which harasses; that which tries the character or principles; that which tempts to evil; as, his child's conduct was a sore trial. "Every station is exposed to some trials." (Rogers)
4. The formal examination of the matter in issue in a cause before a competent tribunal; the mode of determining a question of fact in a court of law; the examination, in legal form, of the facts in issue in a cause pending before a competent tribunal, for the purpose of determining such issue.
Synonym: Test, attempt, endeavor, effort, experiment, proof, essay. See Test, and Attempt.
Origin: From Try.
Source: Websters Dictionary
(01 Mar 1998)
trial and error The apparently random, haphazard, hit-or-miss exploratory activity which often precedes the acquisition of new information or adjustments; it may be overt, as in a rat running in a maze, or covert (vicarious), as when one thinks of various ways of coping with a situation.
(05 Mar 2000)
trial base <cell biology> A hypothetical cell adhesion molecule possibly involved in sponge cell adhesion, existence unproven.
(18 Nov 1997)
trial case In refraction, a box containing lenses for testing.
(05 Mar 2000)
trial denture A setup of artificial teeth so fabricated that it may be placed in the patient's mouth to verify esthetics, for the making of records, or for any other operation deemed necessary before final completion of the denture.
Synonym: wax model denture.
(05 Mar 2000)
trial frame A type of spectacle frame with variable adjustments, for holding trial lenses during refraction.
(05 Mar 2000)
trial lenses A series of cylindrical and spherical lens's used in testing vision.
(05 Mar 2000)
trial of labour Allowing a woman to be in labour long enough to determine if vaginal birth may be anticipated.
(12 Dec 1998)
angiotensin III <chemical> A heptapeptide formed by the enzymatic hydrolysis of angiotensin II. It has greater activity than angiotensin II for stimulating aldosterone synthesis and in the release of prostaglandins but only 20% of the pressor activity.
Chemical name: Angiotensin II, 1-de-L-aspartic acid-
(12 Dec 1998)
annexin III <enzyme> A protein of the annexin family that catalyses the conversion of 1-d-inositol 1,2-cyclic phosphate and water to 1-d-myo-inositol 1-phosphate.
Chemical name: 1-D-myo-Inositol-1,2-cyclic-phosphate 2-inositolphosphohydrolase
Registry number: EC 3.1.4.36
(12 Dec 1998)
antithrombin III <haematology> Antithrombin III is a protein which stimulates the removal of blood clots in the bloodstream.
Small blood clots form normally within the bloodstream, but are normally dissolved via the bodys antithrombin III.
Conditions that may have an associated low value of antithrombin III include: liver disease and DIC. Normal values are: 0.20 to 0.45 mg/ml or more than 50% of the laboratory control value.
Conditions where there is a deficiency of this important protease inhibitor can result in a condition of hypercoagulation, resulting in an increased risk for blood clot formation.
Inheritance: autosomal dominant.
(13 Jan 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • trial
    ÇØº¸±â
  • monkey trial
    ¿ø¼þÀÌ ÀçÆÇ(ÁøÈ­·ÐÆÄ¿Í õÁö âÁ¶ÆÄ °£¿¡ ¹úÀ̰í ÀÖ´Â ÀçÆÇ)
  • trial
    ½Ãµµ;½ÃÇè;½Ã·Ã;°ï¶õ;Àç³­;±ÍÂúÀº »ç¶÷(°Í);ÀçÆÇ;½É¸®;bring to (put on) ~ °øÆÇ¿¡ ºÎÄ¡´Ù;make ~ of ...À» ½ÃÇèÇØ º¸´Ù;on ~ ½ÃÇèÀûÀ¸·Î;½ÃÇèÀÇ °á°ú(·Î);ÃëÁ¶¸¦ ¹Þ°í;~ and error ½ÃÇà Âø¿À
  • trial balance
    ½Ã»êÇ¥
  • trial balloon
    ±â·ù Å½Ãø±â±¸;(¿©·ÐÀ» ¾Ë±âÀ§ÇÑ)½Ã¾È;Á¶±Ý¾¿³»´Â ¹ßÇ¥(µûÀ§)
  • trial horse
    ¿¬½À»ó´ë(ÁÖ·Î ¿¬½À ½ÃÇÕÀ̳ª ½Ã¹ü ½ÃÇÕ¿¡¼­ »ó´ë¿ªÀ» ¸ÃÀº ¼±¼ö)
  • trial jury
    ¼Ò¹è½É
  • trial marriage
    ½ÃÇè °áÈ¥(³²³à°¡ ÇÕÀÇÇÏ¿¡ ÀÏÁ¤±â°£ µ¿¼­ÇÏ´Â °ü°è)
  • trial run
    ½Ã¿îÀü;½Ã½Â
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á